← Eichor
Condition: Melanoma Neoplasms Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Melanoma Neoplasms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06708663Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
NA · 1 location(s) · Goethe University · NCT07161310Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590Precision Medicine for L/GCMN and Melanoma 1
Phase N/A · 1 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT06608420Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT02775643Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adu
Phase N/A · 6 location(s) · University Hospital Tuebingen · NCT06680323The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT07501117Neurocutaneous Melanocytosis Registry
Phase N/A · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT04548817A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Phase 1 · 1 location(s) · Loyola University · NCT02870244An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
Phase N/A · 2 location(s) · National Cancer Institute (NCI) · NCT00040352Efficacy and Safety of Neoadjuvant Cadonilimab Plus High-Dose Recombinant Human Interferon α1b in Stage III/IV Melanoma.
EARLY_Phase 1 · 1 location(s) · Xijing Hospital · NCT07586904Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT05155033Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma
NA · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT05307289DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Phase 2 · 1 location(s) · Oslo University Hospital · NCT06651151FMT to Convert Response to Immunotherapy
Phase 1/Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT05251389APA (Adapted Physical Activity) for Patients With Advanced Melanoma
Phase N/A · 1 location(s) · University Hospital, Rouen · NCT07031830Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT05196087Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Georgiamune Inc · NCT06425926
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.